The stock of Lifecore Biomedical Inc. (NASDAQ:LFCR) increased by $0.16 on Friday to finish at $10.17, up 1.60 percent. The last five days have seen an average of 370,440 shares of common stock traded. 14 times new highs were reached in the current year, with a gain of $3.69. The average number of shares traded over the last 20 days was 300,200, while the average volume over the last 50 days totaled 421,060.
LFCR stock appreciated 2.73% since last month. On 07/14/23, the company’s shares reached a one-month low of $9.58. The stock touched a high of $11.95 on 08/09/23, after rallying from a low of $1.52 in 52 weeks. The price of LFCR stock has risen by 56.94% or $3.69 this year, reaching a new high 14 times. Still, the stock price is down -14.93% from the 52-week high.
Insider Transactions
LFCR stock investors should be aware that Lifecore Biomedical Inc. (LFCR) stock had its last reported insider trading activity 262 days ago on Nov 25. On Nov 25, 10% Owner WYNNEFIELD PARTNERS SMALL CAP acquired 345,260 shares at $7.97 each. This transaction resulted in the insider spending $2,751,722. On Nov 25, WYNNEFIELD PARTNERS SMALL CAP added 282,486 shares at a price of US$7.97. After the transaction, the insider now owns 2,438,180 shares.
Valuation Metrics
Beta for the stock is 1.10. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 2.42, the price-to-book (PB) ratio of 9.00.
Financial Health
For the three months ended February 27, Lifecore Biomedical Inc.’s quick ratio was 1.10, while its current ratio was 2.30, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending February 27 is 3.36, and the total debt to equity ratio is 3.36. As far as profitability goes, gross margin for the trailing twelve months is 24.60% percent. Lifecore Biomedical Inc.’s EBITDA margin for the year ended February 27 was 3.81%, whereas its operating margin stood at -22.40% for the same period. Based on annual data, it had gross profit of $50.37 million and revenue of $185.79 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. LFCR’s return on assets (ROA) during the last 12 months has been -28.40%. There was a -22.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -107.90%.
Earnings Surprise
According to Lifecore Biomedical Inc.’s quarterly financial report for the quarter that ended February 27. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $27.6 million, while revenues rose by 100.0% to $38.8 million. It was predicted that Lifecore Biomedical Inc.’s quarterly earnings would be -$0.22, but it ended up being -$0.13, beating the consensus by -69.20%. EBITDA was -$6.24 million for the quarter. At the end of Lifecore Biomedical Inc.’s most recent quarter ended February 27, its liabilities totaled 163.44 million, while its total debt was $126.94 million. Equity owned by shareholders amounts to $30.32 million.
Technical Picture
Here’s a quick look at Lifecore Biomedical Inc.’s (LFCR) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 47.32%, suggesting the stock is Neutral, with a 36.06% historical volatility rate.
The stochastic %K and %D were 21.81% and 46.86% respectively, while the average true range (ATR) was 0.55. Based on the 14-day stochastic reading of 21.41%, the RSI (14) reading is 52.21%. On the 9-day MACD Oscillator, the stock is at -0.24, and the 14-day reading is at -0.21.
Analyst Ratings
Lifecore Biomedical Inc. (NASDAQ: LFCR) was downgraded by Stephens to a an Equal-weight rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Lifecore Biomedical Inc. (LFCR) an Overweight rating. LFCR is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is LFCR’s price target for the next 12 months?
The current consensus forecast for the stock is between $8.00 and $11.00, with a median target price of $9.50. In analyzing these forecasts, the average price target given by analysts for Lifecore Biomedical Inc. (LFCR) is $9.50.
